Gaudium IVF IPO Subscription Day 1: Issue Subscribed 80% So Far; GMP Signals 10% Listing Gain

The Gaudium IVF ipo subscription opened today, Feb 20th and the public issue was subscribed 80% or 0.80 times at the end of Day 1 with cautious but steady investor response. According to exchange data, the retail category led the demand, with 1.27 times, while the NII category was subscribed to 0.76 times. The QIB portion remained unsubscribed on the first day of bidding.

The Gaudium IVF ipo is a book build issue worth Rs. 165.00 crores. The public offering comprises a fresh issue of 1.14 crore shares aggregating to Rs. 90.00 crores and an offer for sale (OFS) of 0.95 crore shares amounting to Rs. 75.00 crores.

Gaudium IVF IPO Dates and Listing Details

The gaudium IVF ipo bidding dates are scheduled from February 20th to February 24th. The IPO allotment date is expected to be finalized on February 25th, while the tentative Gaudium IVF ipo listing date is fixed as February 27th when the company will debut on both the BSE and NSE.

Gaudium IVF IPO Price Band and Investment Details

The gaudium IVF ipo price band has been fixed at Rs. 75 to Rs. 79 per share. The lot size for retail investors is 189 shares, which translates into a minimum investment of Rs. 14,931 at the upper price band of Rs. 79 per share.

Gaudium IVF IPO GMP Today

According to market sources, the gaudium IVF ipo gmp today stands at Rs. 8.5, last updated on February 20, 2026 at 2:56 PM. Considering the upper price band of Rs. 79, the estimated listing price is projected at Rs. 87.5 (cap price + current GMP).

This implies a potential listing gain of approximately 10.76% per share, making the issue attractive for short-term listing gain for investors.

Should You Watch Gaudium IVF IPO?

Arihant Capital, in its Report Gave a subscribe rating to the IPO. The Brokerage in its report said, "The company's focus on personalised, genome-based solutions enhances clinical differentiation and premium positioning, while diversified revenue streams across IVF, hospital services and pharmacy operations provide operational resilience. With strong clinical credibility, integrated service offerings and scalable infrastructure, the company is strategically placed to drive sustainable growth, improve average revenue per patient, and strengthen its competitive standing in the organised fertility care segment. At the upper band of INR 79, the issue is valued at a P/E ratio of 22.98x, based on Trailing 12 Months EPS of INR 3.4. We are recommending a "Subscribe" rating for this issue."

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.